Marks Group Wealth Management’s GSK GSK Stock Holding History

Marks Group Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.88M	Buy	54,996 +1,666	+3%	+$88.1K	0.25%	107
2026 Q1	$2.94M	Buy	53,330 +8,133	+18%	+$441K	0.28%	105
2025 Q4	$2.22M	Buy	45,197 +4,248	+10%	+$198K	0.21%	118
2025 Q3	$1.77M	Buy	40,949 +1,198	+3%	+$46.8K	0.16%	133
2025 Q2	$1.53M	Sell	39,751 -449	-1%	-$17.2K	0.14%	143
2025 Q1	$1.56M	Buy	40,200 +1,300	+3%	+$47.6K	0.15%	141
2024 Q4	$1.32M	Sell	38,900 -2,044	-5%	-$73.6K	0.13%	152
2024 Q3	$1.67M	Buy	40,944 +1,512	+4%	+$61.9K	0.16%	137
2024 Q2	$1.52M	Sell	39,432 -860	-2%	-$36.2K	0.16%	142
2024 Q1	$1.73M	Sell	40,292 -3,196	-7%	-$132K	0.18%	133
2023 Q4	$1.61M	Sell	43,488 -5,250	-11%	-$188K	0.18%	137
2023 Q3	$1.77M	Buy	+48,738	New	+$1.73M	0.22%	132

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marks Group Wealth Management's GSK Position: Q2 2026 in Review

Marks Group Wealth Management increased its GSK (GSK) stake by 3.1% in Q2 2026, buying an estimated $88.1K and bringing the position to 54,996 shares worth $2.88M. The position accounts for 0.25% of the portfolio, ranked #107.

Marks Group Wealth Management first reported a position in GSK in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.94M in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Marks Group Wealth Management held 54,996 shares of GSK worth $2.88M as of Q2 2026.
Marks Group Wealth Management bought 1,666 GSK shares in Q2 2026, an estimated $88.1K.
GSK made up 0.25% of Marks Group Wealth Management's portfolio in Q2 2026, its #107 holding.
Marks Group Wealth Management first reported a position in GSK in Q3 2023 and has held it in 12 quarters since.
Marks Group Wealth Management's GSK position peaked at $2.94M in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.